A5000930830- CAR-T cell therapy research
- Multiple Myeloma Research and Treatments
- Virus-based gene therapy research
- Viral Infectious Diseases and Gene Expression in Insects
- Platelet Disorders and Treatments
- Advancements in Semiconductor Devices and Circuit Design
- Hematopoietic Stem Cell Transplantation
- Immune Cell Function and Interaction
- Acute Myeloid Leukemia Research
- Integrated Circuits and Semiconductor Failure Analysis
- Cytokine Signaling Pathways and Interactions
- Liver Disease Diagnosis and Treatment
- Immunotherapy and Immune Responses
- Sepsis Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Sirtuins and Resveratrol in Medicine
- Chronic Myeloid Leukemia Treatments
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Nanowire Synthesis and Applications
- Monoclonal and Polyclonal Antibodies Research
- RNA modifications and cancer
- COVID-19 Clinical Research Studies
- Insect Resistance and Genetics
- Healthcare and Venom Research
- Chemokine receptors and signaling
Xuzhou Medical College
2016-2025
Affiliated Hospital of Xuzhou Medical College
2010-2025
Yangzhou University
2025
University of Science and Technology of China
2024
First Affiliated Hospital of Jinan University
2024
Zhengzhou University
2024
Zhejiang University
2024
Jeonbuk National University
2023
Beijing Hospital
2023
Odense University Hospital
2023
Progression to severe disease is a difficult problem in treating coronavirus 2019 (COVID-19). The purpose of this study explore changes markers COVID-19 patients. Sixty-nine patients were included. Patients with showed significant lymphocytopenia. Elevated level lactate dehydrogenase (LDH), C-reactive protein (CRP), ferritin, and D-dimer was found most cases. Baseline interleukin-6 (IL-6) be associated severity. Indeed, the increase baseline IL-6 positively correlated maximal body...
A combination of anti-B-cell maturation antigen (BCMA) and anti-CD19 chimeric receptor (CAR) T cells induced high response rates in patients with relapsed or refractory (R/R) multiple myeloma (MM), but long-term outcomes have not been assessed yet.In this single-arm, phase II trial, R/R MM received a anti-BCMA CAR at dose 1 × 106 cells/kg, after receiving conditioning chemotherapy consisting cyclophosphamide fludarabine. The overall response, outcomes, safety were assessed, as their...
G protein-coupled receptor, class C group 5 member D (GPRC5D) is considered to be a promising surface target for multiple myeloma (MM) immunotherapy. Here, we report the efficacy and safety of anti-GPRC5D chimeric antigen receptor (CAR) T cells in patients with relapsed or refractory (R/R) MM.This phase Ⅱ, single-arm study enrolled (18-70 years) R/R MM. Lymphodepletion was performed before received 2 × 106/kg CAR cells. The primary end point proportion who achieved an overall response....
Despite the high therapeutic response achieved with B-cell maturation antigen (BCMA)-specific chimeric receptor (CAR) T-cell therapy in relapsed and refractory multiple myeloma (R/R MM), primary resistance relapse exist single-target immunotherapy. Here, we design bispecific BC19 CAR T cells targeting BCMA/CD19 evaluate antimyeloma activity vitro vivo. Preclinical results indicate that specifically recognize target antigens, mediate selective killing of BCMA or CD19-positive cancer cells....
Chimeric antigen receptor T (CAR-T) cell therapy has shown promising results for relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL). The immune response induced by murine single-chain variable fragment (scFv) of the CAR may limit CAR-T persistence and thus increases risk relapse. In this study, we developed a novel humanized scFv from FMC63 antibody. A total 18 R/R ALL patients with or without prior CD19 were treated CD19-targeted cells (hCART19s). After lymphodepletion...
The NAD-dependent deacetylase SirT1 regulates factors involved in stress response and cell survival is a potential drug target of activators inhibitors. Determination function tumor cells important for its targeting cancer therapy. We found that knockdown by short hairpin RNA accelerates xenograft formation HCT116 cells, whereas overexpression inhibits formation. Furthermore, pharmacological inhibition stimulates proliferation under conditions growth factor deprivation. Paradoxically, also...
Background The diamondback moth Plutella xyllostella has developed a high level of resistance to the latest insecticide chlorantraniliprole. A better understanding P. xylostella’s mechanism chlorantraniliprole is needed develop effective approaches for management. Principal Findings To provide comprehensive insight into mechanisms xylostella chlorantraniliprole, transcriptome assembly and tag-based digital gene expression (DGE) system were performed using Illumina HiSeq™ 2000. analysis...
Abstract Systematic and dynamic humoral immune reconstitution is little-known for patients with relapsed/refractory (R/R) multiple myeloma (MM) who received anti–B-cell maturation antigen (BCMA) chimeric receptor (CAR) T-cell therapy. We investigated the kinetics of B-cell, normal plasma cell, immunoglobulin recovery in 40 achieved ongoing response after anti-BCMA CAR All developed B-cell aplasia median duration was 70 days (range, 23-270). The count reached its nadir on day 7 returned to...
Clinical trials have confirmed that chimeric antigen receptor (CAR) T cell therapies are revolutionizing approaches for treating several relapsed or refractory hematological tumors. Cytokine release syndrome (CRS) is an adverse event with high incidence during CAR-T treatment. A further understanding of the characteristics and related risk factors CRS important effective management. total 142 patients acute lymphocyte leukemia (ALL), lymphoma, multiple myeloma (MM) received lymphodepletion...
Few studies have described chimeric antigen receptor (CAR) T-cell therapy for patients with B-cell acute lymphoblastic leukemia (B-ALL) central nervous system (CNSL) because of concerns regarding poor response and treatment-related neurotoxicity. Our study included 48 relapsed/refractory B-ALL CNSL to evaluate the efficacy safety CD19-specific CAR T cell–based therapy. The infusion resulted in an overall rate 87.5% (95% confidence interval [CI], 75.3-94.1) bone marrow (BM) disease remission...
Anti-CD30 CAR-T is a potent candidate therapy for relapsed/refractory (r/r) CD30+ lymphomas with limitations, and the efficacy needed to be further improved. Herein multi-center phase II clinical trial (NCT03196830) of anti-CD30 treatment combined PD-1 inhibitor in r/r lymphoma was conducted. After lymphocyte-depleting chemotherapy fludarabine cyclophosphamide, 4 patients cohort 1 3 2 received 106/kg 107/kg cells, respectively, 5 cells anti-PD-1 antibody. The safety cell were analyzed....
Chimeric antigen receptor (CAR)-T cell therapy, a new immunotherapy for relapsed and refractory (R/R) hematologic malignancies, can be accompanied by adverse events, including coagulation disorders. Here, we performed comprehensive analysis of parameters in 100 patients with R/R malignancies after receiving CAR-T therapy to illuminate the profiles disorders facilitate management A high incidence was observed, elevated D-dimer (50/100, 50%), increased fibrinogen degradation product (45/100,...
Bacterial endotoxin has been known to induce excessive inflammatory responses and acute kidney injury. In the present study, we used a mouse model of endotoxemia investigate role Sirt1 in We examined molecular cellular inducible knockout (Sirt1−/−) mice wild type littermates (Sirt1+/+) lipopolysaccharide (LPS)-induced Our studies demonstrated that deletion caused aggravated injury, which was associated with increased including elevated pro-inflammatory cytokine production, ICAM-1 VCAM-1...
Abstract Since December 2019, more than 79,000 people have been diagnosed with infection of the Corona Virus Disease 2019 (COVID-19). A large number medical staff were dispersed for Wuhan city and Hubei province to aid COVID-19 control. Psychological stress, especially vicarious traumatization (VT) caused by pandemic, should not be ignored. To address this concern, study employed a total 214 general public (GP) 526 nurses evaluate VT scores via mobile app-based questionnaire. Results showed...
Abstract Safety and efficacy of allogeneic anti-CD19 chimeric antigen receptor T cells (CAR-T cells) in persons with CD19-positive B-cell acute lymphoblastic leukemia (B-ALL) relapsing after an allotransplant remain unclear. Forty-three subjects B-ALL post received CAR-T were analyzed. 34 (79%; 95% confidence interval [CI]: 66, 92%) achieved complete histological remission (CR). Cytokine release syndrome (CRS) occurred 38 (88%; 78, 98%) was ≥grade-3 7. Two died from multiorgan failure CRS....
Abstract Purpose Anti‐CD19 chimeric antigen receptor T (CAR‐T) cell therapy has demonstrated remarkable efficacy for refractory and relapsed diffuse large B lymphoma (R/R DLBCL). However, this failed in nearly 25% patients mainly due to loss. The authors performed a phase Ⅱ trial by coadministration of anti‐CD19 anti‐CD20 CAR‐T cells treatment R/R DLBCL evaluated its toxicity. Methods Totally 21 with were enrolled study. conditioned fludarabine cyclophosphamide before the infusion cells....
Objective . To investigate the prognostic significance of serum soluble triggering receptor expressed on myeloid cells-1 (sTREM-1), procalcitonin (PCT), N-terminal probrain natriuretic peptide (NT-pro-BNP), C-reactive protein (CRP), cytokines, and clinical severity scores in patients with sepsis. Methods A total 102 sepsis were divided into survival group (<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M1"><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn>60</mml:mn></mml:math>)...
Background. Cluster of differentiation 86 (CD86), also known as B7-2, is a molecule expressed on antigen-presenting cells that provides the costimulatory signals required for T cell activation and survival. CD86 binds to two ligands surface cells: antigen CD28 cytotoxic lymphocyte-associated protein 4 (CTLA-4). By binding CD28, CD86—together with CD80—promotes participation in presentation process. However, interrelationships among CD86, immunotherapy, immune infiltration acute myeloid...
Abstract Relapsed/refractory multiple myeloma patients with extramedullary disease (EMD) have unfavorable prognosis and lack effective therapy. Chimeric antigen receptor (CAR) T‐cell activities in EMD yet to be determined; how EMD‐specific microenvironment influences the clinical outcomes of CAR therapy remains great interest. In this prospective cohort study, histologically confirmed extra‐osseous were enrolled treated combined anti‐BCMA anti‐CD19 from May 2017 September 2023. Thirty‐one...